Contents

Volume 82 Issue 12 | ARD December 2023

Editorial
1503 Lessons from negative phase 3 trials in rheumatoid arthritis anno 2023
R Westhovens, P Verschueren

1506 Time to treat the climate and nature crisis as one indivisible global health emergency
Chris Zielinski, on behalf of the authorship group

Viewpoint
1508 Potential for biosimilars in rheumatology in Africa
M H Abu-Zaid, A Adebojico, Y El Misedany

Review
1511 Contributions of joint damage-related events to gout pathogenesis: new insights from laboratory research
H Xu, H Qin, Y Hua, N Dalketh

Rheumatoid arthritis
1516 Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2)

1527 Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapy: a phase III randomised trial (contRAst 3)

Spondyloarthritis
1558 HLA-B27, axial spondyloarthritis and survival
Z Li, M K Khan, S M van der Linden, B Winkens, P M Villiger, H Baumberger, H van Zandwijk, M A Khan, M A Brown

Systemic sclerosis
1568 Single-cell analysis reveals key differences between early-stage and late-stage systemic sclerosis skin across autoantibody subgroups
K E N Clark, S Xu, M Atash, V H Ong, C D Buckley, C P Denton

Vasculitis
1580 Benralizumab for eosinophilic granulomatosis with polyangiitis

Early arthritis
1538 Disease activity drives transcriptomic heterogeneity in early untreated rheumatoid synovitis
C Traille, G Tilmann, T Sokolova, A Loiion, J Marchandise, S De Montjoye, A Nzeusseu-Toukap, L Méric de Bellefon, C Bouzin, C Galant, P Duraz, B R Luweweny, N Limaye

1547 Directed differentiation of human pluripotent stem cells into articular cartilage reveals effects caused by absence of WISP3, the gene responsible for progressive pseudohumertoid arthropathy of childhood
C Li, M Alemayoh-Ribe, R M Rofer, U Nwoke, M L Warmus, A M Craft

Disclaimer: The Editor of ARD has been granted editorial freedom and ARD is published in accordance with editorial guidelines issued by the World Association of Medical Editors and the Committee on Publication Ethics. ARD is primarily intended for healthcare professionals and its content is for information only. The Journal is published without any guarantee as to its accuracy or completeness and any representations or warranties are expressly excluded to the fullest extent permitted by law. Readers are advised to independently verify any information on which they choose to rely. Acceptance of advertising by ARD does not imply endorsement. Neither EULAR nor BMJ Publishing Group Limited shall have any liability for any loss, injury or damage howsoever arising from ARD except for liability which cannot be legally excluded.

Copyright: © European Association of Sciences for Rheumatology, EULAR 2023. Published by BMJ. All rights reserved.
ARD is published by BMJ Publishing Group Ltd, type set by Exeter Premedia Services Private Ltd, Chennai, India and printed in the UK on acid free paper.
Annals of the Rheumatic Diseases, ISSN 0003-4967 (USPS 21532) is published monthly by BMJ Publishing Group Ltd, BMJ House, Tavistock Square, WC1H 9JR London. Affixes and mailing in the USA by agent named World Container Inc, 150-15, 183rd Street, Jamaica, NY 11413, USA. Periodicals postage paid at Brooklyn, NY 11256. US Postmaster: Send address changes to Annals of the Rheumatic Diseases, World Container Inc, 150-15, 183rd Street, Jamaica, NY 11413, USA. Subscription records are maintained at BMJ House, Tavistock Square, WC1H 9JR London. Air Business Ltd is acting as our mailing agent.

More Contents ▶

This article has been chosen by the Editor to be of special interest or importance and is freely available online.
This article has been made freely available online under the BMJ Journals open access scheme.
See http://authors.bmj.com/open-access/

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics. See http://publicationethics.org/
Autoinflammatory disorders

1594 Spanish cohort of VEXAS syndrome: clinical manifestations, outcome of treatments and novel evidences about UBA1 mosaicism

1637 Low avidity observed for anti-citrullinated peptide antibody is not a general phenomenon for autoantibodies
H Yamada, A Haraguchi, T Tsuru, M Kondo, F Sagawa, H Niño, Y Nakashima

1638 Anti-cyclic citrullinated peptide antibody and pain sensitisation in patients with rheumatoid arthritis: a cross-sectional analysis
Y Y Qiu, T Nego, L N Muhammad, J Song, M B Bolster, W Madler, A C Heisler, A Wohlfeil, D Dunlop, Y C Lee

EULAR news

1642 News from EULAR
EULAR Communications

EULAR communications

1653 Communications on "The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease" by Wallace et al G K Yardmcı, B E S Yildirim, B farisogullari, L Kilic, O Karadağ

1654 Communications on 'NCF1-339 polymorphism is associated with altered formation of neutrophil extracellular traps, high serum interferon activity and antiphospholipid syndrome in systemic lupus erythematosus' by Linge et al G N Goulielmos, M I Zervou, E Eliopoulos

Osteoarthritis

1606 Evaluating the causal effect of circulating proteome on the risk of osteoarthritis-related traits
Y Zhang, J Xie, S Wen, P Cao, W Xiao, J Zhu, S Li, Z Wang, H Cen, Z Zhu, C Ding, C Ruan

Crystal arthropathies

1618 Safety of colchicine and NSAID prophylaxis when initiating urate-lowering therapy for gout: propensity score-matched cohort studies in the UK Clinical Practice Research Datalink
E Reddy, R Bajpai, H Forrestar, R J Partington, C D Mallet, L E Clarson, N Padmanabhan, R Whitle, S Muller

1626 Is colchicine prophylaxis required with start-low go-slow allopurinol dose escalation in gout? A non-inferiority randomised double-blind placebo-controlled trial
L Stamp, A Horne, B Mihov, J Drake, J Haslett, P T Chapman, C Frayn, NP Dalbeth

Electronic pages

e228 Correspondence on "Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry" by Machado et al R Bourguiba, M Delplanque, L. Savey, V Hentgen, G Gatteau, S Georgin-lavialle, French national reference Center for autoinflammatory diseases and AA amyloidosis (CEREMAIA)

e229 Correspondence on "Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial" by Molto et al U Kiltz, J Braun

e230 Correspondence on 'The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease' by Wallace et al G K Yardmcı, B E S Yildirim, B farisogullari, L Kilic, O Karadağ

e231 Correspondence on 'NCF1-339 polymorphism is associated with altered formation of neutrophil extracellular traps, high serum interferon activity and antiphospholipid syndrome in systemic lupus erythematosus' by Linge et al G N Goulielmos, M I Zervou, E Eliopoulos

Images in rheumatology

1635 Finger ischaemia, enlarged spleen and lung nodules
X Pauchet, L Delaval, P Blanche